# Assessing the Impact of Genratest on Women With Recurrent Implantation Failure: A Single-Center Study

## TL;DR

This study evaluated whether Genratest improves pregnancy outcomes in women with recurrent implantation failure but found no significant differences between personalized and standard embryo transfer methods.

## Contribution

The study provides new evidence on the effectiveness of Genratest in clinical pregnancy outcomes for RIF patients.

## Key findings

- Genratest identified a displaced window of implantation in 90% of RIF patients.
- Personalized embryo transfer did not significantly improve clinical pregnancy, ongoing pregnancy, or live birth rates compared to standard transfer.
- Miscarriage rates were similar between the two groups.

## Abstract

Objective

Recurrent implantation failure (RIF) is a significant challenge in assisted reproduction. Genratest has emerged as a potential tool to identify the displaced window of implantation (WOI). This study aimed to evaluate the impact of this test on the pregnancy outcomes of RIF patients.

Methods

A retrospective analysis was conducted on 143 RIF patients who were categorized into two groups: the personalized embryo transfer (pET, n=69) group and standard embryo transfer (sET, n=74) group. The main measured outcomes were clinical pregnancy, ongoing pregnancy, miscarriage, and live birth rates.

Results

Genratest effectively diagnoses the displaced WOI in 90% of RIF patients. The pET group exhibited a higher rate of clinical pregnancy (n=36/69, 52.2%) compared to the sET group (n=35/74, 47.3%), but this difference was not statistically significant (p=0.679). Ongoing pregnancy rates were comparable between the pET (n=28/69, 40.6%) and the sET (n=30/74, 40.5%) groups (p=0.996). Live birth rates showed no statistically significant difference between the two groups (n=26/69, 37.7% versus n=22/74, 29.7%, p=0.407). Miscarriage rates were similar in both groups (n=9/69, 13% versus n=11/74, 14.9%, p=0.942).

Conclusions

pET based on the results of the Genratest did not show a significant improvement in pregnancy outcomes, including clinical pregnancy, ongoing pregnancy, live birth, or miscarriage rates. Further research is needed to identify the role of Genratest in RIF patients.